Covered recipient · General Payments record
GEORGE CHIU YI CHANG CHIEN
Allopathic & Osteopathic Physicians Pain Medicine Interventional Pain Medicine
General Payments · PY2018–2024
$4,470.19
- Reported across 134 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $817.27 | 33 |
| Consulting Fee | $345.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $349.69 | 27 |
| VERTEX PHARMACEUTICALS INCORPORATED | $345.00 | 1 |
| Abbott Laboratories | $171.33 | 1 |
| BIOTRONIK NRO, Inc. | $107.32 | 1 |
| Medtronic, Inc. | $76.74 | 1 |
| SPR Therapeutics, Inc | $73.31 | 1 |
| UCB, Inc. | $38.88 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $171.33 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134594463 | CMS |
| ABBVIE INC. | $21.92 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443040 | CMS |
| ABBVIE INC. | $2.36 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443042 | CMS |
| ABBVIE INC. | $10.45 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443044 | CMS |
| ABBVIE INC. | $4.52 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443046 | CMS |
| ABBVIE INC. | $9.16 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443048 | CMS |
| ABBVIE INC. | $20.70 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443050 | CMS |
| ABBVIE INC. | $0.91 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443052 | CMS |
| ABBVIE INC. | $11.07 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443054 | CMS |
| ABBVIE INC. | $21.50 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443056 | CMS |
| ABBVIE INC. | $26.13 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443058 | CMS |
| ABBVIE INC. | $12.04 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443060 | CMS |
| ABBVIE INC. | $2.71 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443062 | CMS |
| ABBVIE INC. | $8.35 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443064 | CMS |
| ABBVIE INC. | $12.39 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443066 | CMS |
| ABBVIE INC. | $10.17 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443068 | CMS |
| ABBVIE INC. | $14.41 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443070 | CMS |
| ABBVIE INC. | $10.76 | 06/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443072 | CMS |
| ABBVIE INC. | $9.96 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443074 | CMS |
| ABBVIE INC. | $18.90 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443076 | CMS |
| ABBVIE INC. | $24.94 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443078 | CMS |
| ABBVIE INC. | $6.77 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443080 | CMS |
| ABBVIE INC. | $19.58 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443082 | CMS |
| ABBVIE INC. | $21.23 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443084 | CMS |
| ABBVIE INC. | $10.85 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443086 | CMS |
| ABBVIE INC. | $9.21 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443088 | CMS |
| ABBVIE INC. | $15.11 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443090 | CMS |
| ABBVIE INC. | $13.59 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103443092 | CMS |
| BIOTRONIK NRO, Inc. | $107.32 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153858148 | CMS |
| Medtronic, Inc. | $76.74 | 10/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119278042 | CMS |
| SPR Therapeutics, Inc | $73.31 | 02/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104952132 | CMS |
| UCB, Inc. | $15.16 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143099638 | CMS |
| UCB, Inc. | $23.72 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143099640 | CMS |
| VERTEX PHARMACEUTICALS INCORPORATED | $345.00 | 11/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105912510 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.